A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery
暂无分享,去创建一个
David M. Wilson | F. Gamo | J. Garcia-Bustos | D. Leroy | L. Shultz | M. Jiménez-Díaz | Iñigo Angulo-Barturen | S. Ferrer | Javier Ibáñez | Sara Viera | Félix Calderón | Esther Fernández | Helen Garuti | N. Magán-Marchal | Teresa Mulet | Vanessa Gómez | Lorena Cortés-Gil | Antonio Martínez | M. T. Fraile | J. García-Bustos
[1] N. White,et al. Qinghaosu (Artemisinin): The Price of Success , 2008, Science.
[2] P. Rosenthal,et al. A Murine Model of falciparum-Malaria by In Vivo Selection of Competent Strains in Non-Myelodepleted Mice Engrafted with Human Erythrocytes , 2008, PloS one.
[3] L. Slater. Malarial Birds: Modeling Infectious Human Disease in Animals , 2005, Bulletin of the history of medicine.
[4] K. Kinnamon,et al. Biological screening in the U.S. Army antimalarial drug development program. , 1975, The American journal of tropical medicine and hygiene.
[5] N. Tamimi,et al. Drug Development: From Concept to Marketing! , 2009, Nephron Clinical Practice.
[6] G. V. Paolini,et al. Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.
[7] Supa Hannongbua,et al. In-silico ADME models: a general assessment of their utility in drug discovery applications. , 2011, Current topics in medicinal chemistry.
[8] Iñigo Angulo-Barturen,et al. Humanised models of infection in the evaluation of anti-malarial drugs. , 2013, Drug discovery today. Technologies.
[9] Bradley I. Coleman,et al. Aminoindoles, a Novel Scaffold with Potent Activity against Plasmodium falciparum , 2011, Antimicrobial Agents and Chemotherapy.
[10] Dongmei Zhang,et al. Construction of Transgenic Plasmodium berghei as a Model for Evaluation of Blood-Stage Vaccine Candidate of Plasmodium falciparum Chimeric Protein 2.9 , 2009, PloS one.
[11] L. Shultz,et al. Improved Murine Model of Malaria Using Plasmodium falciparum Competent Strains and Non-Myelodepleted NOD-scid IL2Rγnull Mice Engrafted with Human Erythrocytes , 2009, Antimicrobial Agents and Chemotherapy.
[12] J. Derisi,et al. The Transcriptome of the Intraerythrocytic Developmental Cycle of Plasmodium falciparum , 2003, PLoS biology.
[13] R. Ricklefs,et al. A Molecular Clock for Malaria Parasites , 2010, Science.
[14] Peter G. Schultz,et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen , 2008, Proceedings of the National Academy of Sciences.
[15] D. Wirth,et al. High-Throughput Plasmodium falciparum Growth Assay for Malaria Drug Discovery , 2006, Antimicrobial Agents and Chemotherapy.
[16] Chris J Janse,et al. A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. , 2004, Molecular and biochemical parasitology.
[17] W. Peters,et al. Chapter 92 – Malaria , 1999 .
[18] Jeremy N. Burrows,et al. P. falciparum In Vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-Action , 2012, PloS one.
[19] James R. Brown,et al. Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.
[20] P. Olliaro,et al. The Global Portfolio of New Antimalarial Medicines Under Development , 2009, Clinical pharmacology and therapeutics.
[21] D. Doolan,et al. High-throughput multi-parameter flow-cytometric analysis from micro-quantities of plasmodium-infected blood. , 2011, International journal for parasitology.
[22] A. Dash,et al. Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India , 2012, Malaria Journal.
[23] A. Cohen,et al. Adult and child malaria mortality in India: a nationally representative mortality survey , 2010, The Lancet.
[24] José María Bueno,et al. An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS. , 2011, ACS medicinal chemistry letters.
[25] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[26] P. McGreevy,et al. Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo. , 1995, The American journal of tropical medicine and hygiene.
[27] Aldert H Piersma,et al. Strategies for the optimisation of in vivo experiments in accordance with the 3Rs philosophy. , 2012, Regulatory toxicology and pharmacology : RTP.
[28] F. Cohen,et al. Searching for New Antimalarial Therapeutics amongst Known Drugs , 2006, Chemical biology & drug design.
[29] Félix Calderón,et al. A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold. , 2012, ACS medicinal chemistry letters.
[30] K. Silamut,et al. Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.
[31] NJ White,et al. The parasite clearance curve , 2011, Malaria Journal.
[32] D. Terlouw,et al. Azithromycin for treating uncomplicated malaria. , 2011, The Cochrane database of systematic reviews.
[33] S. Meshnick,et al. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. , 2007, The American journal of tropical medicine and hygiene.
[34] Michael P Barrett,et al. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. , 2003, Trends in parasitology.
[35] Kelly Chibale,et al. The state of the art in anti-malarial drug discovery and development. , 2011, Current topics in medicinal chemistry.
[36] D. Fidock,et al. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum , 2011, Current opinion in infectious diseases.
[37] K. Batty,et al. Pharmacokinetics, Pharmacodynamics, and Allometric Scaling of Chloroquine in a Murine Malaria Model , 2011, Antimicrobial Agents and Chemotherapy.
[38] Jeremy N. Burrows,et al. Cyclopropyl Carboxamides, a Chemically Novel Class of Antimalarial Agents Identified in a Phenotypic Screen , 2011, Antimicrobial Agents and Chemotherapy.
[39] P. E. Thompson,et al. Antimalarial Agents: Chemistry and Pharmacology , 2012 .
[40] David A. Fidock,et al. Antimalarial drug discovery: efficacy models for compound screening , 2004, Nature Reviews Drug Discovery.
[41] M. Jiménez-Díaz,et al. Improvement of detection specificity of Plasmodium‐infected murine erythrocytes by flow cytometry using autofluorescence and YOYO‐1 , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[42] Yongyuth Yuthavong,et al. A Research Agenda for Malaria Eradication: Drugs , 2011, PLoS medicine.
[43] Kamolrat Silamut,et al. Estimation of the Total Parasite Biomass in Acute Falciparum Malaria from Plasma PfHRP2 , 2005, PLoS medicine.
[44] Paul D Leeson,et al. Lessons learned from candidate drug attrition. , 2010, IDrugs : the investigational drugs journal.
[45] Anang A. Shelat,et al. Chemical genetics of Plasmodium falciparum , 2010, Nature.
[46] Dale C. Smith,et al. History of U.S. military contributions to the study of malaria. , 2005, Military medicine.
[47] S. Meshnick,et al. Efficacy of DB289 in Thai patients with Plasmodium vivax or acute, uncomplicated Plasmodium falciparum infections. , 2005, The Journal of infectious diseases.
[48] Yuexin Li,et al. Quinolone-3-Diarylethers: A New Class of Antimalarial Drug , 2013, Science Translational Medicine.
[49] Bruce Russell,et al. A rapid and robust tri-color flow cytometry assay for monitoring malaria parasite development , 2011, Scientific reports.
[50] Weltgesundheitsorganisation. World malaria report , 2005 .
[51] Melanie Rug,et al. Targeting Malaria Virulence and Remodeling Proteins to the Host Erythrocyte , 2004, Science.
[52] R. Sidwell,et al. Handbook of Animal Models of Infection , 1999 .
[53] J. Jensen,et al. Antimalarial activity of azithromycin and erythromycin against Plasmodium berghei. , 1993, The American journal of tropical medicine and hygiene.
[54] P. Rosenthal,et al. Multiple Antibiotics Exert Delayed Effects against the Plasmodium falciparum Apicoplast , 2007, Antimicrobial Agents and Chemotherapy.
[55] Junmei Wang,et al. Structure – ADME relationship : still a long way to go ? , 2008 .
[56] Jun O. Liu,et al. A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.
[57] Simon J F Macdonald,et al. Cyclopropyl Carboxamides: A New Oral Antimalarial Series Derived from the Tres Cantos Anti-Malarial Set (TCAMS). , 2011, ACS medicinal chemistry letters.
[58] N. White,et al. Therapeutic Responses to Quinine and Clindamycin in Multidrug-Resistant Falciparum Malaria , 2000, Antimicrobial Agents and Chemotherapy.